The concern from the FDA comes after the dye was found to cause cancer in rats during testing.
Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), executed a sale of 5,584 American Depositary Shares (ADS) on January ...
In a recent transaction, William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback